暂无数据
暂无内容
暂无数据
暂无数据
暂无数据
为什么Vaxxinity股票的交易价格下跌了约55%?以下是周一午盘交易中其他股票的走势
Vaxxinity, Inc.(纳斯达克股票代码:VAXX)的股价在周一的交易中大幅下跌,此前该公司宣布打算自愿退市并注销其A类普通股。
Benzinga04/22 13:26 (美东)
MRIN、WISA 和 SMFL 是午间推动者
Seeking Alpha04/22 12:52 (美东)
周一盘中交易时段,12只医疗保健类股走势
周一的例行中,GainersNKGen Biotech(纳斯达克股票代码:NKGN)股价上涨33.8%,至1.48美元。该公司的市值为3,370万美元。该公司第四季度的收益是在4天前公布的。MSP Rec
Benzinga04/22 12:31 (美东)
Inhibikase Therapeutics申请出售普通股和认股权证
Seeking Alpha04/19 17:26 (美东)
Inhibikase Therapeutics向股东通报未来计划的最新情况
TipRanks04/19 06:13 (美东)
快讯 | Inhibikase Therapeutics——201试验的双盲阶段完成后,我们预计将要求在2024年底之前结束与美国食品药品管理局的第二阶段会议
Moomoo 24/704/18 16:30 (美东)
Jaguar8 : Love this!
Trytosaveabit楼主 Jaguar8: Yup yup! I kinda dig it as well!
taijahmed75 Trytosaveabit楼主: do you know any reason for the big fall today? Such a good stock….
Trytosaveabit楼主 taijahmed75: Im guessing it because they said to shareholders Friday there is a big concern whether they will have enough money to continue
taijahmed75 Trytosaveabit楼主: Oh ok, thank you
Trytosaveabit楼主 : We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval," said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. "Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission," noted Dr. Werner.
暂无数据
暂无数据